Scot Dowden

8.6k total citations
24 papers, 826 citations indexed

About

Scot Dowden is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Scot Dowden has authored 24 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in Scot Dowden's work include Pancreatic and Hepatic Oncology Research (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Scot Dowden is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Scot Dowden collaborates with scholars based in Canada, United States and Spain. Scot Dowden's co-authors include Braden Manns, Flora Au, Steven J. Heitman, Robert J. Hilsden, Sharlene Gill, Malcolm J. Moore, Muhammad Zulfiqar, Pablo Cano, Paweł Zalewski and Sukhbinder Dhesy‐Thind and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Scot Dowden

24 papers receiving 813 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scot Dowden Canada	14	624	285	188	177	124	24	826
Sandra J. Casak United States	18	455 0.7×	215 0.8×	189 1.0×	107 0.6×	114 0.9×	32	1.0k
A. Azzedine France	6	733 1.2×	422 1.5×	228 1.2×	214 1.2×	84 0.7×	8	972
May Cho United States	17	507 0.8×	222 0.8×	178 0.9×	120 0.7×	99 0.8×	57	834
Matthew Burge Australia	19	703 1.1×	224 0.8×	170 0.9×	215 1.2×	52 0.4×	123	1.1k
Karen Rittweger United States	14	967 1.5×	367 1.3×	280 1.5×	106 0.6×	173 1.4×	17	1.3k
Toshiki Masuishi Japan	18	694 1.1×	424 1.5×	196 1.0×	137 0.8×	53 0.4×	158	1.1k
Kanwal Raghav United States	19	568 0.9×	349 1.2×	369 2.0×	199 1.1×	175 1.4×	52	1.1k
Natsuko Okita Japan	20	855 1.4×	518 1.8×	271 1.4×	135 0.8×	91 0.7×	110	1.3k
Thomas J. Semrad United States	15	395 0.6×	237 0.8×	122 0.6×	162 0.9×	44 0.4×	51	890
Ettore D’Argento Italy	18	538 0.9×	382 1.3×	105 0.6×	160 0.9×	114 0.9×	52	890

Countries citing papers authored by Scot Dowden

Since Specialization

Citations

This map shows the geographic impact of Scot Dowden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scot Dowden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scot Dowden more than expected).

Fields of papers citing papers by Scot Dowden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scot Dowden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scot Dowden. The network helps show where Scot Dowden may publish in the future.

Co-authorship network of co-authors of Scot Dowden

This figure shows the co-authorship network connecting the top 25 collaborators of Scot Dowden. A scholar is included among the top collaborators of Scot Dowden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scot Dowden. Scot Dowden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Philip, P. A., Jill Lacy, Alberto F. Sobrero, et al.. (2017). nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals of Oncology. 28. v212–v212. 2 indexed citations

Nixon, Nancy, Omar Khan, Patricia A. Tang, et al.. (2017). Drug development for breast, colorectal, and non–small cell lung cancers from 1979 to 2014. Cancer. 123(23). 4672–4679. 17 indexed citations

Tehfé, Mustapha, Scot Dowden, Hagen F. Kennecke, et al.. (2016). nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Advances in Therapy. 33(5). 747–759. 16 indexed citations

Mulder, Karen, Corinne Doll, Scot Dowden, et al.. (2016). Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11–12 September 2015. Current Oncology. 23(6). 425–434. 4 indexed citations

Philip, Philip Agop, Jill Lacy, Scot Dowden, et al.. (2016). LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology. 34(4_suppl). TPS477–TPS477. 3 indexed citations

Gill, Sharlene, Yoo‐Joung Ko, C. Cripps, et al.. (2016). PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology. 34(32). 3914–3920. 180 indexed citations

Gill, Sharlene, Scot Dowden, Bruce Colwell, Loretta L. Collins, & Scott Berry. (2014). Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews. 40(10). 1171–1181. 13 indexed citations

Gill, Sharlene, Yoo‐Joung Ko, M. Christine Cripps, et al.. (2014). PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).. Journal of Clinical Oncology. 32(15_suppl). 4022–4022. 37 indexed citations

Karanicolas, Paul J., Peter Metrakos, Kelvin Chan, et al.. (2013). Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Current Oncology. 21(1). 129–129. 44 indexed citations

10.

Heitman, Steven J., et al.. (2012). Correction: Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. PLoS Medicine. 9(11). 1 indexed citations

11.

Heitman, Steven J., Robert J. Hilsden, Flora Au, Scot Dowden, & Braden Manns. (2010). Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. PLoS Medicine. 7(11). e1000370–e1000370. 110 indexed citations

12.

Cripps, C., Sharlene Gill, Shahid Ahmed, et al.. (2010). Consensus Recommendations for the Use of Anti-EGFR Therapies in Metastatic Colorectal Cancer. Current Oncology. 17(6). 39–45. 7 indexed citations

13.

Dixon, Elijah, Christopher Armstrong, Guy J. Maddern, et al.. (2009). Development of Quality Indicators of Care for Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer Using a Delphi Process. Journal of Surgical Research. 156(1). 32–38.e1. 27 indexed citations

14.

Bathe, Oliver F., Scott Ernst, Francis Sutherland, et al.. (2009). A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 9(1). 156–156. 29 indexed citations

15.

McKay, Andrew, et al.. (2009). Population-based review of the outcomes following hepatic resection in a Canadian health region.. PubMed. 52(1). 12–7. 10 indexed citations

16.

Maroun, Jean A., Lowell Anthony, Normand Blais, et al.. (2007). Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. 14(1). 13–20. 109 indexed citations

17.

Urbanski, Stefan J., Naurang Singh Mangat, Andrew McKay, et al.. (2007). Colorectal liver metastases contract centripetally with a response to chemotherapy. Cancer. 112(2). 362–371. 48 indexed citations

18.

Bathe, Oliver F., S. Ernst, Francis Sutherland, et al.. (2005). A phase II study of neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer. Journal of Clinical Oncology. 23(16_suppl). 3662–3662. 3 indexed citations

19.

Bathe, Oliver F., Scot Dowden, Francis Sutherland, et al.. (2004). Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4(1). 32–32. 27 indexed citations

20.

Davis, Thomas A., David G. Maloney, A.J. Grillo-López, et al.. (2000). Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.. PubMed. 6(7). 2644–52. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact